TFCP2 Antibody #14826

The transcription factor CP2 (TFCP2, LSF) is a ubiquitous nuclear protein that was initially shown to bind and activate the alpha-globin promoter in erythroid cells (1). Research studies show that TFCP2 functions as an oncogene in hepatocellular carcinoma (HCC) cells. Overexpression of TFCP2 is seen in HCC patient samples and cell lines; TFCP2 expression correlates with high tumor grade and poor prognosis (2). Forced expression of TFCP2 in less aggressive HCC cells results in highly aggressive, angiogenic and metastatic tumors, while inhibition of TFCP2 abrogates growth and metastasis of highly aggressive HCC cells (2). Additional studies show that TFCP2 acts downstream of Notch1 in HCC cells, where it mediates Notch pathway signaling during proliferation and invasion of hepatocellular carcinoma (3). TFCP2 functions as an oncogene as it upregulates multiple genes involved in angiogenesis, cell invasion, and chemoresistance, including osteopontin, metalloproteinase-9, fibronectin 1, tight junction protein 1, and thymidylate synthase (2-5). Factor quinolinone inhibitor 1 (FQI1) is a small molecule inhibitor of TFCP2 that inhibits TFCP2 DNA-binding activity, reduces expression of TFCP2 target genes, and rapidly induces cell death in TFCP2-overexpressing HCC cell lines (6).